Quantum BioPharma Ltd. (QNTM)
NASDAQ: QNTM · Real-Time Price · USD
2.940
-0.170 (-5.47%)
At close: Oct 9, 2026, 4:00 PM EDT
2.980
+0.040 (1.36%)
After-hours: Oct 9, 2026, 7:42 PM EDT
Quantum BioPharma Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
17
Market Cap
23.78M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Immutep | 13.79M |
| Evaxion | 7.49M |
| Kyntra Bio | 4.62M |
| Seres Therapeutics | 1.88M |
| BeyondSpring | 1.88M |
| ABVC BioPharma | 797.92K |
| Cocrystal Pharma | 330.00K |
| aTyr Pharma | 190.00K |
QNTM News
- 4 days ago - Quantum BioPharma signs contract with Thermo Fisher for sclerosis trial - TheFly
- 4 days ago - Quantum BioPharma Signs Contract with Thermo Fisher Scientific's Clinical Research Business to Implement Phase 2 Lucid-MS Trial in Multiple Sclerosis - GlobeNewsWire
- 10 days ago - IBN Announces Latest Episode of The BioMedWire Podcast Featuring the Return of Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd. - GlobeNewsWire
- 16 days ago - Quantum BioPharma licensee Unbuzzed Wellness appoints Zapolin as CEO - TheFly
- 16 days ago - Quantum Biopharma Licensee Unbuzzd Wellness to Advance Clinically Validated Alcohol Metabolism Accelerant After Appointing Zappy as CEO - GlobeNewsWire
- 23 days ago - Rodman & Renshaw Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$8 Price Target - GlobeNewsWire
- 25 days ago - Quantum BioPharma to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto - Newsfile Corp
- 26 days ago - NetworkNewsAudio Announces Audio Press Release (APR) Discussing FDA Clearance for Trial of First-in-Class Treatment Creating ‘Rare Moment' in MS Research - GlobeNewsWire